公开(公告)号：US20170049769A1

公开(公告)日：2017-02-23

申请号：US15344631

申请日：2016-11-07

申请人： Acura Pharmaceuticals, Inc.

发明人： Vijai KUMAR ,  David DIXON ,  Divya TEWARI ,  Dilip B. WADGAONKAR

IPC分类号： A61K31/485 ,  A61K9/20

CPC分类号： A61K31/485 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2059 ,  A61K9/2095 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2893 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

摘要： This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.

摘要翻译： 本发明涉及治疗性药物组合物，其包含：包含阿片样物质的混合物; 该聚环氧乙烷的量为组合物的约3至约40重量％; 崩解剂 和表面活性剂; 其中所述崩解剂以足以使所述药物组合物呈现立即释放曲线的量存在。

公开(公告)号：US20210077484A1

公开(公告)日：2021-03-18

申请号：US17104374

申请日：2020-11-25

申请人： Acura Pharmaceuticals, Inc.

发明人： Vijai KUMAR ,  David DIXON ,  Divya TEWARI ,  Dilip B. WADGAONKAR

IPC分类号： A61K31/485 ,  A61K9/20 ,  A61K9/28 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

摘要： This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.

公开(公告)号：US20180028527A1

公开(公告)日：2018-02-01

申请号：US15725738

申请日：2017-10-05

申请人： Acura Pharmaceuticals, Inc.

发明人： Vijai KUMAR ,  David DIXON ,  Divya TEWARI ,  Dilip B. WADGAONKAR

IPC分类号： A61K31/485 ,  A61K47/32 ,  A61K47/38 ,  A61K47/34 ,  A61K9/20 ,  A61K9/28

CPC分类号： A61K31/485 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2059 ,  A61K9/2095 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2893 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

摘要： This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.